GlassScriptPhysician profile
Deborah L Winiger
NPI 1639178726
$9,191.67
in general payments reported to CMS, 2019-2025
42 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $850 · 2021: $2,406 · 2022: $928 · 2023: $1,206 · 2024: $1,197 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,651.70 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,258.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,182.77 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,155.96 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $823.89 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $759.58 | 2019-2025 | Prolia, Evenity, Prolia |
| Pfizer INC. | $647.72 | 2019-2025 | |
| Abbvie INC. | $509.34 | 2020-2025 | Ubrelvy, Viberzi, Linzess |
| Merck Sharp & Dohme LLC | $506.28 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Novo Nordisk INC | $424.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $288.54 | 2019-2022 | |
| Sanofi Pasteur INC. | $163.25 | 2019-2025 | |
| Exact Sciences Corporation | $158.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $130.90 | 2019-2025 | Austedo Xr |
| Abbott Laboratories | $126.47 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $99.94 | 2019-2025 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Winiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.